Bicara Therapeutics (NASDAQ:BCAX) Price Target Cut to $41.00 by Analysts at HC Wainwright

Bicara Therapeutics (NASDAQ:BCAX) had its target price lowered by HC Wainwright from $44.00 to $41.00 in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Bicara Therapeutics’ FY2026 earnings at ($2.59) EPS.

A number of other equities analysts have also recently issued reports on BCAX. Wedbush reiterated an “outperform” rating and set a $31.00 target price on shares of Bicara Therapeutics in a report on Thursday, March 27th. Wells Fargo & Company began coverage on Bicara Therapeutics in a report on Thursday, April 17th. They issued an “underweight” rating and a $8.00 price objective for the company. Stifel Nicolaus set a $48.00 price objective on Bicara Therapeutics in a report on Thursday, March 27th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $13.01 price objective on shares of Bicara Therapeutics in a report on Thursday, March 13th. One equities research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $32.00.

Bicara Therapeutics Stock Performance

BCAX stock opened at $14.47 on Friday. The stock has a 50-day moving average price of $12.81 and a two-hundred day moving average price of $15.20. Bicara Therapeutics has a 1 year low of $8.91 and a 1 year high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX) last released its earnings results on Tuesday, May 13th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.28). As a group, equities research analysts forecast that Bicara Therapeutics will post -2.59 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Bicara Therapeutics

Hedge funds have recently modified their holdings of the stock. Red Tree Management LLC acquired a new stake in Bicara Therapeutics in the 4th quarter valued at about $55,230,000. Vestal Point Capital LP lifted its stake in Bicara Therapeutics by 290.0% in the 1st quarter. Vestal Point Capital LP now owns 2,768,975 shares of the company’s stock valued at $36,080,000 after purchasing an additional 2,058,975 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its stake in Bicara Therapeutics by 171.9% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 2,175,265 shares of the company’s stock valued at $37,893,000 after purchasing an additional 1,375,265 shares during the last quarter. Braidwell LP lifted its stake in Bicara Therapeutics by 8.1% in the 1st quarter. Braidwell LP now owns 2,162,803 shares of the company’s stock valued at $28,181,000 after purchasing an additional 162,144 shares during the last quarter. Finally, Deep Track Capital LP lifted its stake in Bicara Therapeutics by 151.0% in the 4th quarter. Deep Track Capital LP now owns 2,000,000 shares of the company’s stock valued at $34,840,000 after purchasing an additional 1,203,148 shares during the last quarter.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.